环己-1-烯基甲基-甲基醚 | 10300-05-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 环己-1-烯基甲基-甲基醚
• 英文名称: 1-Methoxymethyl-cyclohexen
• 英文别名: 1-(Methoxymethyl)cyclohexene
• CAS: 10300-05-7
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: PJKUTAWNHBAHJP-UHFFFAOYSA-N

物化性质

• 沸点：
  156 °C
• 密度：
  0.9139 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  环己-1-烯基甲基-甲基醚 在 氢溴酸 作用下， 生成 1-Methoxymethyl-1-brom-cyclohexan
  参考文献：
  名称：

  Shikhmamedbekova,A.Z. et al., Journal of Organic Chemistry USSR (English Translation), 1979, vol. 15, p. 1688 - 1693

  摘要：

  DOI：
• 作为产物：
  描述：

  1-溴-1-溴甲基环己烷 在 甲醇 、 sodium methylate 作用下， 生成 环己-1-烯基甲基-甲基醚
  参考文献：
  名称：

  Mousseron; Granger; Merle, Bulletin de la Societe Chimique de France, 1947, p. 459,460

  摘要：

  DOI：

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Synthesis and Comparative Antibacterial Activity of Verdamicin C2 and C2a. A New Oxidation of Primary Allylic Azides in Dihydro[2<i>H</i>]pyrans
  作者：Stephen Hanessian、Janek Szychowski、J. Pablo Maianti

  DOI：10.1021/ol802421d

  日期：2009.1.15

  A synthesis of verdamicin C2 and its congener C2a has been accomplished from sisomicin relying on a novel oxidative transformation of an allylic azide to the corresponding α,β-unsaturated aldehyde, and its stereocontrolled elaboration into the intended 5′ side chain of verdamicin C2 and C2a. In vitro antibacterial testing shows that both C6′ epimers in verdamicin C2 and C2a are equally active against

  威索霉素C2及其同类物C2a的合成已由sisomicin依赖于烯丙基叠氮化物向相应的α，β-不饱和醛的新型氧化转化以及其立体控制的精制成维达霉素C2和C2a的预期5'侧链。体外抗菌测试表明，维达霉素C2和C2a中的C6'差向异构体均对多种细菌菌株具有同等活性。2-取代的二氢[2 H ]吡喃的烯丙基伯叠氮化物，醚和酯与SeO 2的氧化直接导致相应的醛。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• [EN] ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE COMME BLOQUEURS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2011058766A1

  公开（公告）日：2011-05-19

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or -SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及式（I）的芳基羧酰胺衍生物，其中Ar1为苯基；Ar2为芳基；n为1-4；X为-O-、-S-、-SO-或-SO2-，其前体药物或其药学上可接受的盐，具有作为TTX-S通道的电压门控钠通道的阻塞活性，并且在治疗或预防涉及电压门控钠通道的疾病和疾病中如疼痛等方面具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病如疼痛中的用途。